Video Experimental Relacionado
Updated: Aug 7, 2026
12:37
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
Efectos del minoxidil en la hemodinámica en pacientes con insuficiencia cardíaca congestiva
Circulation
|March 1, 1981
Resumen
El minoxidil se muestra prometedor como un vasodilatador arterial eficaz para pacientes con insuficiencia cardíaca, ofreciendo efectos potentes y duraderos con una toxicidad potencialmente menor que los tratamientos actuales.
Área de la Ciencia:
- Cardiología Cardiología.
- Farmacología Farmacología.
- Medicina interna es la medicina interna de las enfermedades.
Sus antecedentes:
- Los vasodilatadores actuales para la insuficiencia cardíaca crónica (ICC) tienen limitaciones: los nitratos son principalmente venodilatadores, la prazosina causa tolerancia y la hidralazina tiene toxicidad crónica.
- El manejo óptimo de la insuficiencia cardíaca congestiva requiere agentes dilatantes arteriales efectivos con perfiles de seguridad mejorados.
Objetivo del estudio:
- Evaluar los efectos hemodinámicos agudos de una dosis única de minoxidil en pacientes con insuficiencia ventricular izquierda crónica.
Principales métodos:
- Dieciocho pacientes con insuficiencia ventricular izquierda crónica (cardiomiopatía isquémica o primaria) recibieron una dosis oral única de minoxidil.
- Se midieron los parámetros hemodinámicos, incluidos la frecuencia cardíaca, la presión arterial media, el índice cardíaco, la resistencia vascular sistémica y varias presiones.
- Los efectos máximos se evaluaron a las 5 horas, y los efectos se monitorearon durante al menos 8 horas después de la administración.
Principales resultados:
- El minoxidil aumentó significativamente el índice cardíaco (2.34 a 2.95 l/min/m2) y disminuyó la resistencia vascular sistémica (19.6 a 15.0 unidades).
- Se observó un ligero aumento en la frecuencia cardíaca (85,4 a 90,9 latidos por minuto) y una ligera disminución en la presión arterial media (88,0 a 84,9 mm Hg).
- El minoxidil no alteró significativamente las presiones del atrio derecho, la arteria pulmonar o la cuña pulmonar, y sus efectos persistieron durante al menos 8 horas.
Conclusiones:
- El minoxidil actúa como un agente dilatante arterial eficaz en pacientes con insuficiencia cardíaca, similar a la hidralazina pero con una potencia y duración potencialmente mayores.
- Su acción prolongada y su toxicidad aguda relativamente baja sugieren que el minoxidil puede ser un valioso vasodilatador para controlar la insuficiencia cardíaca.
- Se justifica una mayor evaluación de los efectos a largo plazo del minoxidil en la insuficiencia cardíaca.
Más Videos Relacionados
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
Videos de Conceptos Relacionados
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.